Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

256 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Brief Report: Impact of COVID-19 on Cabotegravir Plus Rilpivirine Long-Acting Dosing Across 6 Ongoing Global Phase IIb and III Clinical Trials.
Czarnogorski M, Benn P, McCoig C, Nwafor T, Griffith S, Sutton K, Harrington C, Saggu P, Yague I, Williams W, Español CM, Goodchild J, Fricker J, Patel P, D'Amico R. Czarnogorski M, et al. Among authors: benn p. J Acquir Immune Defic Syndr. 2022 Oct 1;91(2):157-161. doi: 10.1097/QAI.0000000000003031. Epub 2022 Jun 4. J Acquir Immune Defic Syndr. 2022. PMID: 36094481
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.
Jaeger H, Overton ET, Richmond G, Rizzardini G, Andrade-Villanueva JF, Mngqibisa R, Hermida AO, Thalme A, Belonosova E, Ajana F, Benn PD, Wang Y, Hudson KJ, Español CM, Ford SL, Crauwels H, Margolis DA, Talarico CL, Smith KY, van Eygen V, Van Solingen-Ristea R, Vanveggel S, Spreen WR. Jaeger H, et al. Lancet HIV. 2021 Nov;8(11):e679-e689. doi: 10.1016/S2352-3018(21)00185-5. Epub 2021 Oct 11. Lancet HIV. 2021. PMID: 34648734 Clinical Trial.
Population pharmacokinetics of cabotegravir following administration of oral tablet and long-acting intramuscular injection in adult HIV-1-infected and uninfected subjects.
Han K, Baker M, Lovern M, Paul P, Xiong Y, Patel P, Moore KP, Seal CS, Cutrell AG, D'Amico RD, Benn PD, Landovitz RJ, Marzinke MA, Spreen WR, Ford SL. Han K, et al. Among authors: benn pd. Br J Clin Pharmacol. 2022 Oct;88(10):4607-4622. doi: 10.1111/bcp.15439. Epub 2022 Jul 4. Br J Clin Pharmacol. 2022. PMID: 35695476 Free PMC article.
Week 96 extension results of a Phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatment.
Swindells S, Lutz T, Van Zyl L, Porteiro N, Stoll M, Mitha E, Shon A, Benn P, Huang JO, Harrington CM, Hove K, Ford SL, Talarico CL, Chounta V, Crauwels H, Van Solingen-Ristea R, Vanveggel S, Margolis DA, Smith KY, Vandermeulen K, Spreen WR. Swindells S, et al. Among authors: benn p. AIDS. 2022 Feb 1;36(2):185-194. doi: 10.1097/QAD.0000000000003025. AIDS. 2022. PMID: 34261093 Free PMC article. Clinical Trial.
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.
Overton ET, Richmond G, Rizzardini G, Jaeger H, Orrell C, Nagimova F, Bredeek F, García Deltoro M, Swindells S, Andrade-Villanueva JF, Wong A, Khuong-Josses MA, Van Solingen-Ristea R, van Eygen V, Crauwels H, Ford S, Talarico C, Benn P, Wang Y, Hudson KJ, Chounta V, Cutrell A, Patel P, Shaefer M, Margolis DA, Smith KY, Vanveggel S, Spreen W. Overton ET, et al. Among authors: benn p. Lancet. 2021 Dec 19;396(10267):1994-2005. doi: 10.1016/S0140-6736(20)32666-0. Epub 2020 Dec 9. Lancet. 2021. PMID: 33308425 Clinical Trial.
Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M).
Chounta V, Overton ET, Mills A, Swindells S, Benn PD, Vanveggel S, van Solingen-Ristea R, Wang Y, Hudson KJ, Shaefer MS, Margolis DA, Smith KY, Spreen WR. Chounta V, et al. Patient. 2021 Nov;14(6):849-862. doi: 10.1007/s40271-021-00524-0. Epub 2021 May 31. Patient. 2021. PMID: 34056699 Free PMC article. Clinical Trial.
Using Climate-HIV to describe real-world clinical outcomes for people living with HIV taking dolutegravir-based regimens.
Okoli C, Schwenk A, Radford M, Myland M, Taylor S, Barnes J, Fox A, Darley A, Grimson F, Reeves I, Munshi S, Croucher A, Boxall N, Paice A, van Wyk J, Benn P. Okoli C, et al. Among authors: benn p. Int J STD AIDS. 2021 Oct;32(12):1165-1173. doi: 10.1177/09564624211027099. Epub 2021 Jun 22. Int J STD AIDS. 2021. PMID: 34156330 Free PMC article.
Pooled specimens for HIV RNA monitoring: cheaper, but is it reliable?
El Bouzidi K, Grant P, Edwards S, Benn P, Pillay D, Waters L, Nastouli E. El Bouzidi K, et al. Among authors: benn p. Clin Infect Dis. 2014 Nov 1;59(9):1346-7. doi: 10.1093/cid/ciu562. Epub 2014 Jul 16. Clin Infect Dis. 2014. PMID: 25034422 No abstract available.
256 results